Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Adenocarcinoma × Atu027 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Pancreatic Ductal 1 Adenocarcinoma 1

Interventions

Gemcitabine 6 pembrolizumab 5 Paclitaxel 4 Capecitabine 4 Nivolumab 3 Fluorouracil 3 Cyclophosphamide 3 Carboplatin 3 Albumin-Bound Paclitaxel 3 sargramostim 2 poly ICLC 2 fludarabine 2 Prednisone 2 Oxaliplatin 2 Irinotecan 2 Dexamethasone 2 Cisplatin 2 130-nm albumin-bound paclitaxel 2 tegafur-gimeracil-oteracil 1 spartalizumab 1 sintilimab 1 rucaparib 1 resiquimod 1 repotrectinib 1 regorafenib 1 pralsetinib 1 olaparib 1 lenvatinib 1 dabrafenib 1 belinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01808638 2016-03-11

Atu027-I-02

Silence Therapeutics GmbH

Phase 1/2 Completed

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡